MANTLE CELL LYMPHOMA

# Relapsed MCL in fitter (CAR-T eligible) patients

**First-line relapse**

**At relapse**
- Simplified MIPI
- Repeat CT imaging: extranodal/nodal bulk > 5 cm
- Repeat biopsy: Ki67%, morphology, TP53 mutation status (or on PB sample if lymphocytosis)

**High-risk features**
- POD24
- Blastoid morphology
- Ki67 > 30%
- TP53 mutated
- High sMIPI

**Discuss at network MDT**
Agree cases to be referred pre-emptively to CAR-T centre

**High-risk features**

- 4-weekly face-to-face review for 12 weeks
- Repeat imaging at 4 weeks if no/minimal clinical improvement
- Repeat imaging at 8–12 weeks if clinical improvement

**2L ibrutinib**

**No high-risk features**

**2L ibrutinib until PD**
Consider routine imaging

**CR**

**PR**

**SD/PD**

Close monitoring with at least 6-monthly re-imaging

Continue ibrutinib and/or bridging therapy (? pirtobrutinib, ? CIT)

**CAR-T**

**Consider allograft referral**
Shared decision making with patient